On Demand Webinar: Humanized Mouse Models for I/O Drug Development

Immunotherapeutics have proven to be a game changer in oncology, but suitable preclinical platforms are required to address questions about how to optimize immuno-oncology (I/O) agent use, including those which combine patient tumor xenografts with functional human immune systems. Given the complexity of human tumor-bearing humanized mice, the key to study success using these models is through combining an in-depth knowledge of each model’s immunological features and limitations with an appropriate study design based on the specific questions being addressed—resulting in highly relevant models for progressing I/O agents.

As part of our Tech Talk series “In Vivo Solutions and Models for Oncology Drug Development” Dr. Gerold Feuer shares his expertise in humanized mouse models and provides a guide on which platforms and models to use in specific I/O studies.

Watch this webinar to learn about:

• Comparison of MiXeno™ and Hu CD34+ humanized mouse models for in vivo oncology studies
  
  
• Evaluating I/O therapies in humanized mice
  
  
• Engraftment of cell line- (CDX) and patient-derived xenografts (PDX) in humanized mouse platform

Watch Now!

About The Presenter:

Gerold Feuer, PhD, Senior Director, Scientific Research & Innovation, Crown Bioscience

Dr. Gerold Feuer was Founder and Chief Scientific Officer of HuMurine Technologies, Inc. Dr. Feuer obtained his BA at U.C. Berkeley and his PhD at U.C. Irvine. After post-doctoral studies at U.C.L.A. Medical Center on human retrovirus infections in humanized mice, Dr. Feuer spent 18 years as a professor in the Department of Microbiology and Immunology at SUNY Upstate Medical University, Syracuse, where he established and served as the Director of SUNY UMU’s Center for Humanized SCID Mouse Models. Humurine was founded in 2008 as a SUNY- academic spinoff company, and HuMurine laboratory operations relocated adjacent to the U.C. Davis Medical Center and Institute for Regenerative Cures in Sacramento, CA, in 2011. Dr. Feuer retired from SUNY UMU in 2015 to return to California and to run HuMurine full-time. Dr. Feuer has published over 35 publications and has an extensive background in the fields of human virology, immuno-oncology, gene therapies and human hematopoietic stem cells.